|
2025 Conference Publication The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with cystic fibrosisDuplancic, C., Alene, K., Ballard, E., Thomson, R., Wainwright, C., Rogers, G., Clements, A., Floto, A., Bell, S. and O. NTM in CF Investigators (2025). The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis. 2025 North American Cystic Fibrosis Conference, Seattle, WA United States, 22-25 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(25)01654-6 |
|
2025 Conference Publication The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studiesEvans, I., Duplancic, C., Kidd, T., Ballard, E., Thomson, R., Wainwright, C., Bell, S. and O. NTM in CF Investigators (2025). The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studies. 2025 North American Cystic Fibrosis Conference, Seattle, WA United States, 22-25 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(25)01642-x |
|
2025 Conference Publication Mycobacteria acquisition from potable water across the drinking water system in AustraliaRamsay, K., Smith, K., Duplancic, C., Taylor, S., Rogers, G., Wainwright, C., Thomson, R. and Bell, S. (2025). Mycobacteria acquisition from potable water across the drinking water system in Australia. 2025 North American Cystic Fibrosis Conference, Seattle, WA United States, 22-25 October 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(25)01643-1 |
|
2025 Conference Publication Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trialWainwright, C., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). Adverse events related to study drugs in finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT) trial. 48th European Cystic Fibrosis Conference, Milan, Italy, 4-7 June 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.jcf.2025.03.118 |
|
2025 Conference Publication Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trialWainwright, C., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A., Thomson, R., Grimwood, K., Bell, S. and Clark, J. (2025). Prevalence of nausea and vomiting and anti-emetic use in the tinding the optimal regimen for Mycobacterium abscessus treatment (Format) trial. 48th European Cystic Fibrosis Conference, Milan, Italy, 4-7 June 2025. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.jcf.2025.03.119 |
|
2025 Conference Publication Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary DiseaseTwining, M., Kang, S., Riddles, T., Evans, I., Burke, A.J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a5444 |
|
2025 Conference Publication Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A. J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. 52nd Critical Care Congress of the Society of Critical Care Medicine (SCCM), San Francisco, CA United States, 21-24 January 2023. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Efficacy of ethambutol rechallenge in patients with prior ethambutol-induced optic toxicity for the treatment of mycobacterium avium complex pulmonary diseaseYeo, B., Goh, F. and Thomson, R. (2025). Efficacy of ethambutol rechallenge in patients with prior ethambutol-induced optic toxicity for the treatment of mycobacterium avium complex pulmonary disease. ATS International Conference, San Francisco, CA USA, 16-21 May 2025. New York, NY USA: American Thoracic Society. |
|
2025 Conference Publication Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Prevalence of Nausea and Vomiting and Anti-emetic Use in the Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (FORMaT) Trial. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7277 |
|
2025 Conference Publication Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A. J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. 52nd Critical Care Congress of the Society of Critical Care Medicine (SCCM), San Francisco, CA United States, 21-24 January 2023. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) TrialThomson, R., Hicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Burke, A.J., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2025). Adverse Events Related to Study Drugs in Finding the Optimal Regimen for Mycobacteroides Abscessus Treatment (Format) Trial. ATS International Conference, San Francisco, CA, United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm.2025.211.abstracts.a7278 |
|
2025 Conference Publication Gut microbiome signatures discriminate nontuberculous mycobacterial pulmonary disease patients requiring treatment from those with stable diseaseThompson, R., Lim, Y., Goh, F., Blumenthal, A., Morrison, M. and Thomson, R. (2025). Gut microbiome signatures discriminate nontuberculous mycobacterial pulmonary disease patients requiring treatment from those with stable disease. ATS International Conference, San Francisco, CA USA, 16-21 May 2025. New York, NY USA: American Thoracic Society. |
|
2025 Conference Publication Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary DiseaseTwining, M., Kang, S., Riddles, T., Evans, I., Burke, A. J. and Thomson, R. (2025). Real-world Experience With Inhaled Liposomal Amikacin Suspension for Treatment of Nontuberculous Mycobacterial Pulmonary Disease. ATS International Conference, San Francisco, CA United States, 16-21 May 2025. New York, NY United States: American Thoracic Society. |
|
2025 Conference Publication Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trialHicks, D., Rice, M., Jong, T., Gailer, N., Joshi, S., Wang, X., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C. (2025). Adverse events related to study drugs in finding the optimal regimen for mycobacterium abscessus treatment (format) trial. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons. |
|
2025 Conference Publication The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CFDuplancic, C., Alene, K., Thomson, R., Wainwright, C., Rogers, G., Clements, A., Floto, A. and Bell, S. (2025). The aetiology and epidemiology of nontuberculous mycobacteria (NTM) in Australians with CF. TSANZSRS Annual Scientific meeting 2025, Adelaide, SA Australia, 21-25 March 2025. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsHaworth, Charles, Shteinberg, Michal, Winthrop, Kevin, Barker, Alan, Blasi, Francesco, Dimakou, Katerina, Morgan, Lucy, O'Donnell, Anne, Ringhausen, Felix, Sibila, Oriol, Thomson, Rachel, Carroll, Kevin, Pontenani, Federica, Castellani, Paola and Chalmers, James (2024). Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: Results of two randomized double-blind placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. 2024 ERS Congress, Vienna, Austria, 7–11 September 2024. Sheffield, United Kingdom: European Respiratory Society. doi: 10.1183/13993003.congress-2024.rct5390 |
|
2024 Conference Publication Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trialRice, Megan, Hicks, Daniel, Jong, Tiffany, Gailer, Nicolas, Joshi, Sri, Stevens, Luke, Lee, Kate, Thomson, Rachel, Burke, Andrew, Grimwood, Keith, Bell, Scott, Clark, Julia and Wainwright, Claire E. (2024). Developing a pharmacovigilance framework for an investigator led, non-commercial international adaptive platform trial. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national studyDuplancic, Christine, Wainwright, Claire, Thomson, Rachel, Rogers, Geraint, Clements, Archie, Floto, Andre and Bell, Scott (2024). Nontuberculous mycobacteria (NTM) in Australians with cystic fibrosis (CF): A national study. 15th Australasian Cystic Fibrosis Conference, Brisbane, QLD, Australia, 2–4 August 2024. Richmond, VIC, Australia: John Wiley & Sons. |
|
2024 Conference Publication Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT)Hicks, D., Jong, T., Rice, M., Gailer, N., Joshi, S., Stevens, L., Lee, K., Thomson, R., Burke, A., Grimwood, K., Bell, S., Clark, J. and Wainwright, C.E. (2024). Developing a pharmacovigilance framework for an investigator-led, non-commercial platform trial – finding the optimal regimen for Mycobacterium abscessus treatment (FORMaT). 47th European Cystic Fibrosis Conference, Glasgow, United Kingdom, 5-8 June 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s1569-1993(24)00244-3 |
|
2024 Conference Publication Validation of the BACES Severity Scoring System in an Australian Cohort of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Patients Mishiro, K., Ballard, E., Goh, F. and Thomson, R. (2024). Validation of the BACES Severity Scoring System in an Australian Cohort of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Patients . American Thoracic Society International Conference 2024, San Diego, CA United States, 17-22 May 2024. New York, NY United States: American Thoracic Society. doi: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3158 |
